Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting

Executive Summary

Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee
Advertisement

Related Content

Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Biotechs Gain On Favorable M&A Landscape; Will Deal Prices Keep Rising?
Biotechs Gain On Favorable M&A Landscape; Will Deal Prices Keep Rising?
Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint
Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Aranesp Anemia Of Cancer Study Results Show Increased Mortality Risk
Aranesp Anemia Of Cancer Study Results Show Increased Mortality Risk
Advertisement
UsernamePublicRestriction

Register

PS048314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel